These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 29176433)

  • 1. Drug updates and approvals: 2017 in review.
    Mospan G; Mospan C; Vance S; Bradshaw A; Meosky K; Bowles K
    Nurse Pract; 2017 Dec; 42(12):8-16. PubMed ID: 29176433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Saxagliptin/Dapagliflozin: A Review in Type 2 Diabetes Mellitus.
    Garnock-Jones KP
    Drugs; 2017 Mar; 77(3):319-330. PubMed ID: 28176222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug updates and approvals: 2014 in review.
    Sigler J
    Nurse Pract; 2014 Dec; 39(12):14-23; quiz 23-4. PubMed ID: 25350291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COMBINED TREATMENT WITH SAXAGLIPTIN PLUS DAPAGLIFLOZIN REDUCES INSULIN LEVELS BY INCREASED INSULIN CLEARANCE AND IMPROVES β-CELL FUNCTION.
    Ekholm E; Hansen L; Johnsson E; Iqbal N; Carlsson B; Chen H; Hirshberg B
    Endocr Pract; 2017 Mar; 23(3):258-265. PubMed ID: 27849380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes.
    Bailey CJ; Del Prato S; Wei C; Reyner D; Saraiva G
    Diabetes Obes Metab; 2019 Nov; 21(11):2564-2569. PubMed ID: 31364269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug updates and approvals: 2018 in review.
    Mospan C; Mospan G; Byland E; Whitaker WB; Xiong L; Dunlap J; Canupp K
    Nurse Pract; 2018 Dec; 43(12):23-32. PubMed ID: 30379711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA approves saxagliptin for type 2 diabetes.
    Traynor K
    Am J Health Syst Pharm; 2009 Sep; 66(17):1513. PubMed ID: 19710429
    [No Abstract]   [Full Text] [Related]  

  • 9. New drugs 2015, part 2.
    Hussar DA
    Nursing; 2015 Jul; 45(7):34-41; quiz 41-2. PubMed ID: 26083291
    [No Abstract]   [Full Text] [Related]  

  • 10. Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.
    Med Lett Drugs Ther; 2018 Mar; 60(1543):55-56. PubMed ID: 29635266
    [No Abstract]   [Full Text] [Related]  

  • 11. Safinamide mesylate, Brodalumab, Guselkumab, and Abaloparatide.
    Hussar DA; Kotova M
    J Am Pharm Assoc (2003); 2018; 58(1):123-127. PubMed ID: 29290341
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug updates and approvals: 2019 in review.
    Crump LH; Benfield M; Ramey C; Arcara A; Yang S; Brown J; Mospan G; Mospan C
    Nurse Pract; 2019 Dec; 44(12):21-32. PubMed ID: 31658218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case Report: DKA with Lower-than-Expected Blood Glucose in the Setting of SGLT2 Inhibitor Use.
    Voskertchian A; Milanes L
    Am Fam Physician; 2021 Feb; 103(4):200. PubMed ID: 33587584
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
    Mathieu C; Ranetti AE; Li D; Ekholm E; Cook W; Hirshberg B; Chen H; Hansen L; Iqbal N
    Diabetes Care; 2015 Nov; 38(11):2009-17. PubMed ID: 26246458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects.
    Tang W; Engman H; Zhu Y; Dayton B; Boulton DW
    Clin Ther; 2019 Aug; 41(8):1545-1563. PubMed ID: 31266654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.
    Dey J
    Postgrad Med; 2017 May; 129(4):409-420. PubMed ID: 28322073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin approved for type 2 diabetes.
    Traynor K
    Am J Health Syst Pharm; 2014 Feb; 71(4):263. PubMed ID: 24481146
    [No Abstract]   [Full Text] [Related]  

  • 18. Safinamide: first global approval.
    Deeks ED
    Drugs; 2015 Apr; 75(6):705-11. PubMed ID: 25851099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Drugs 2019, part 1.
    Hussar DA
    Nursing; 2019 Feb; 49(2):28-36. PubMed ID: 30676555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Market watch: Upcoming market catalysts in Q4 2015.
    Liu M
    Nat Rev Drug Discov; 2015 Oct; 14(10):671. PubMed ID: 26338153
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.